Drug intelligence / Profile preview

RG-CLDN18.2

Development stage: Unknown
Lead developer: Hangzhou Ronggu Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

RG-CLDN18.2 (also known as CB CAR-NK182) is an investigational cord blood-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Hangzhou RonGu Biotechnology. The therapy utilizes a lentivirus-transduced, nanobody-based CAR to target Claudin-18.2 (CLDN18.2), a tight junction protein highly expressed in gastric and pancreatic cancers. By directing NK cells specifically to CLDN18.2-expressing tumor cells, RG-CLDN18.2 is designed to induce targeted tumor cell lysis. It is currently in Phase 1/IIT clinical development for the treatment of gastric cancer and pancreatic cancer.

Other names: CB-CAR-NK182CB-CAR-NK-182CB-CAR-NK 182Cord Blood-Derived CAR-NK Cells therapy (Rongu Biotechnology)

Beyond the preview

Go deeper on RG-CLDN18.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-CLDN18.2.

Explore the full profile